If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I – REGISTRANT INFORMATION

ERBA Diagnostics, Inc.

Full Name of Registrant

Former Name if Applicable

14100 NW 57 ^th Court

Address of Principal Executive Office (Street and Number)

Miami Lakes, Florida 33014

City, State and Zip Code

PART II – RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

PART III – NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

As previously reported, during the third quarter of 2015, ERBA Diagnostics implemented, among other things, a new, enhanced balance sheet review process, with a particular focus on reconciliation of significant accounts, including, among others, intercompany accounts and corresponding eliminations made, or required to be made at the consolidated level, and their potential impact on ERBA Diagnostics’ consolidated financial statements. In the course of implementing such new, enhanced review process, ERBA Diagnostics identified materially out of balance accounts evident in the elimination process and noted erroneous recording of transactions to such intercompany and other accounts for each of the years ended December 31, 2014 and 2013 and for each of the interim periods ended March 31, 2015 and June 30, 2015 (the “Restatement Periods”). As previously reported, ERBA Diagnostics intends to restate its financial statements for the Restatement Periods. ERBA Diagnostics intends to include the restated financial statements for the Restatement Periods and ERBA Diagnostics’ financial statements as of and for the year ended December 31, 2015 in a Comprehensive Annual Report on Form 10-K.

ERBA Diagnostics is working diligently to complete the Comprehensive Annual Report on Form 10-K but was not able to complete the Comprehensive Annual Report on Form 10-K without unreasonable effort or expense by August 15, 2016. Accordingly, while ERBA Diagnostics is also working diligently to complete its Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, ERBA Diagnostics was also not able to complete the Quarterly Report on Form 10-Q without unreasonable effort or expense by August 15, 2016.

As previously reported, ERBA Diagnostics received letters from the NYSE MKT LLC (the “NYSE MKT”) stating that ERBA Diagnostics’ failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 is a violation of the continued listing standards of the NYSE MKT’s Company Guide and is viewed by the NYSE MKT as one continuing late filing deficiency. As previously reported, ERBA Diagnostics submitted a plan of remediation and compliance, as amended (the “Plan”), to the NYSE MKT and the NYSE MKT accepted the Plan and granted ERBA Diagnostics an extension until November 25, 2016 to regain compliance with the NYSE MKT’s Company Guide.

ERBA Diagnostics is working diligently to regain compliance with the NYSE MKT’s Company Guide.

PART IV – OTHER INFORMATION

(1)           Name and telephone number of person to contact in regard to this notification

Quarterly Report on Form 10-Q for the quarter ended September 30, 2015                                                                         

Annual Report on Form 10-K for the year ended December 31, 2015                                                                                   

Quarterly Report on Form 10-Q for the quarter ended March 31, 2016                                                                                

(3)           Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?                                                  Yes ☒         No ☐

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

See Part III above.

FORWARD-LOOKING INFORMATION

ERBA Diagnostics has made forward-looking statements, which are subject to risks and uncertainties and which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, in this Notification of Late Filing on Form 12b-25. Forward-looking statements may be preceded by, followed by or otherwise include the words “may,” “will,” “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates,” “projects,” “could,” “would,” “should,” or similar expressions or statements that certain events or conditions may occur. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by these forward-looking statements. These forward-looking statements are based largely on ERBA Diagnostics’ expectations and the beliefs and assumptions of ERBA Diagnostics’ management and on the information currently available to it and are subject to a number of risks and uncertainties, including, but not limited to, the risk that: ERBA Diagnostics may not be able to file the Comprehensive Annual Report on Form 10-K or the Quarterly Reports on Form 10-Q for the quarters ended September 30, 2015, March 31, 2016 and June 30, 2016, on or prior to the date anticipated, that ERBA Diagnostics may not regain or maintain compliance with the continued listing standards of the NYSE MKT, and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. See also the section entitled “Risk Factors” in ERBA Diagnostics’ Annual Report on Form 10-K for the year ended December 31, 2014 for further discussion of certain risks and uncertainties that could materially and adversely affect ERBA Diagnostics’ business, operating results or financial condition. Many of these factors are beyond ERBA Diagnostics’ control.

                                    ERBA Diagnostics, Inc.                                     

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 16 , 201 6                                                                          By:       /s/ Mohan Gopalkrishnan                        

Name:      Mohan Gopalkrishnan

Title:      Chief Executive Officer

4